Pharmacokinetic considerations in drug dosing to pediatric obese patients
Farmakokinetička razmatranja u doziranju lekova pedijatrijskim gojaznim pacijentima
Abstract
Since the incidence of obesity continues to increase globally, this source of disposition variability remains a significant issue for clinicians. The prevalence of overweight and obese children has increased worldwide, causing substantial concern over proper therapeutic dosing in this population. Pharmacotherapy in these patients represents a major challenge in the clinical practice, because obese patients are, often excluded from the clinical trials. Consequently, data on drugs' pharmacokinetics (PK) in this population of patients are scarce, incomplete and/or inconclusive. It is previously observed that different degrees of obesity may change the PK profile of drug. Consequently, there is a need for the descriptors of size of the organism that best describes the changes in the composition of the organism in obese patients, and the one that best predicts key PK parameters that define dosage regimen. Changes in PK parameters of certain drugs are clinically important in the obese childr...en and adolescent patients, requiring changes in usual dosage regimen.
Obzirom da se globalno uočava kontinuiran porast incidence gojaznih osoba, gojaznost kao faktor varijabilnosti u dispoziciji leka postaje vrlo značajan aspekt razmatranja za kliničare. Prevalenca dece sa prekomernom telesnom masom i gojazne dece se povećava u svetu, dovodeći do nedoumica u pogledu pravilnog doziranja lekova u ovoj populaciji. Farmakoterapija ovih pacijenata predstavlja veliki izazov u kliničkoj praksi, jer su gojazne osobe, često isključene iz kliničkih ispitivanja. Stoga, podaci o farmakokinetici (FK) lekova u ovoj populaciji pacijenata su često oskudni, nepotpuni i/ili nisu utemeljeni na jakim dokazima. Primećeno je da različiti stepen gojaznosti može promeniti FK profil leka. Shodno tome, postoji potreba za deskriptorima veličine organizma koji najbolje opisuju promene u sastavu organizma kod gojaznih pacijenata, ali i definisati onaj koji najbolje predviđa vrednosti ključnih parametara FK koji definišu režim doziranja. Promene u FK parametrima određenih lekovakod ...gojazne dece i adolescenata imaju klinički značaj, što zahteva korekcije uobičajenih režima doziranja.
Keywords:
variability / children / body mass index / varijabilnost / deca / indeks telesne maseSource:
MD - Medical data, 2016, 8, 3, 149-153Publisher:
- Most Art doo, Beograd
Funding / projects:
- Basic and Clinical Pharmacological research of mechanisms of action and drug interactions in nervous and cardiovascular system (RS-MESTD-Basic Research (BR or ON)-175023)
Collections
Institution/Community
PharmacyTY - JOUR AU - Vučićević, Katarina AU - Miljković, Branislava AU - Prostran, Milica PY - 2016 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2553 AB - Since the incidence of obesity continues to increase globally, this source of disposition variability remains a significant issue for clinicians. The prevalence of overweight and obese children has increased worldwide, causing substantial concern over proper therapeutic dosing in this population. Pharmacotherapy in these patients represents a major challenge in the clinical practice, because obese patients are, often excluded from the clinical trials. Consequently, data on drugs' pharmacokinetics (PK) in this population of patients are scarce, incomplete and/or inconclusive. It is previously observed that different degrees of obesity may change the PK profile of drug. Consequently, there is a need for the descriptors of size of the organism that best describes the changes in the composition of the organism in obese patients, and the one that best predicts key PK parameters that define dosage regimen. Changes in PK parameters of certain drugs are clinically important in the obese children and adolescent patients, requiring changes in usual dosage regimen. AB - Obzirom da se globalno uočava kontinuiran porast incidence gojaznih osoba, gojaznost kao faktor varijabilnosti u dispoziciji leka postaje vrlo značajan aspekt razmatranja za kliničare. Prevalenca dece sa prekomernom telesnom masom i gojazne dece se povećava u svetu, dovodeći do nedoumica u pogledu pravilnog doziranja lekova u ovoj populaciji. Farmakoterapija ovih pacijenata predstavlja veliki izazov u kliničkoj praksi, jer su gojazne osobe, često isključene iz kliničkih ispitivanja. Stoga, podaci o farmakokinetici (FK) lekova u ovoj populaciji pacijenata su često oskudni, nepotpuni i/ili nisu utemeljeni na jakim dokazima. Primećeno je da različiti stepen gojaznosti može promeniti FK profil leka. Shodno tome, postoji potreba za deskriptorima veličine organizma koji najbolje opisuju promene u sastavu organizma kod gojaznih pacijenata, ali i definisati onaj koji najbolje predviđa vrednosti ključnih parametara FK koji definišu režim doziranja. Promene u FK parametrima određenih lekovakod gojazne dece i adolescenata imaju klinički značaj, što zahteva korekcije uobičajenih režima doziranja. PB - Most Art doo, Beograd T2 - MD - Medical data T1 - Pharmacokinetic considerations in drug dosing to pediatric obese patients T1 - Farmakokinetička razmatranja u doziranju lekova pedijatrijskim gojaznim pacijentima VL - 8 IS - 3 SP - 149 EP - 153 UR - https://hdl.handle.net/21.15107/rcub_farfar_2553 ER -
@article{ author = "Vučićević, Katarina and Miljković, Branislava and Prostran, Milica", year = "2016", abstract = "Since the incidence of obesity continues to increase globally, this source of disposition variability remains a significant issue for clinicians. The prevalence of overweight and obese children has increased worldwide, causing substantial concern over proper therapeutic dosing in this population. Pharmacotherapy in these patients represents a major challenge in the clinical practice, because obese patients are, often excluded from the clinical trials. Consequently, data on drugs' pharmacokinetics (PK) in this population of patients are scarce, incomplete and/or inconclusive. It is previously observed that different degrees of obesity may change the PK profile of drug. Consequently, there is a need for the descriptors of size of the organism that best describes the changes in the composition of the organism in obese patients, and the one that best predicts key PK parameters that define dosage regimen. Changes in PK parameters of certain drugs are clinically important in the obese children and adolescent patients, requiring changes in usual dosage regimen., Obzirom da se globalno uočava kontinuiran porast incidence gojaznih osoba, gojaznost kao faktor varijabilnosti u dispoziciji leka postaje vrlo značajan aspekt razmatranja za kliničare. Prevalenca dece sa prekomernom telesnom masom i gojazne dece se povećava u svetu, dovodeći do nedoumica u pogledu pravilnog doziranja lekova u ovoj populaciji. Farmakoterapija ovih pacijenata predstavlja veliki izazov u kliničkoj praksi, jer su gojazne osobe, često isključene iz kliničkih ispitivanja. Stoga, podaci o farmakokinetici (FK) lekova u ovoj populaciji pacijenata su često oskudni, nepotpuni i/ili nisu utemeljeni na jakim dokazima. Primećeno je da različiti stepen gojaznosti može promeniti FK profil leka. Shodno tome, postoji potreba za deskriptorima veličine organizma koji najbolje opisuju promene u sastavu organizma kod gojaznih pacijenata, ali i definisati onaj koji najbolje predviđa vrednosti ključnih parametara FK koji definišu režim doziranja. Promene u FK parametrima određenih lekovakod gojazne dece i adolescenata imaju klinički značaj, što zahteva korekcije uobičajenih režima doziranja.", publisher = "Most Art doo, Beograd", journal = "MD - Medical data", title = "Pharmacokinetic considerations in drug dosing to pediatric obese patients, Farmakokinetička razmatranja u doziranju lekova pedijatrijskim gojaznim pacijentima", volume = "8", number = "3", pages = "149-153", url = "https://hdl.handle.net/21.15107/rcub_farfar_2553" }
Vučićević, K., Miljković, B.,& Prostran, M.. (2016). Pharmacokinetic considerations in drug dosing to pediatric obese patients. in MD - Medical data Most Art doo, Beograd., 8(3), 149-153. https://hdl.handle.net/21.15107/rcub_farfar_2553
Vučićević K, Miljković B, Prostran M. Pharmacokinetic considerations in drug dosing to pediatric obese patients. in MD - Medical data. 2016;8(3):149-153. https://hdl.handle.net/21.15107/rcub_farfar_2553 .
Vučićević, Katarina, Miljković, Branislava, Prostran, Milica, "Pharmacokinetic considerations in drug dosing to pediatric obese patients" in MD - Medical data, 8, no. 3 (2016):149-153, https://hdl.handle.net/21.15107/rcub_farfar_2553 .